摘要
目的:观察新辅助化疗联合腹腔镜宫颈癌根治术治疗子宫颈鳞状细胞癌患者的效果。方法:选取2018年3月至2019年3月该院收治的104例子宫颈鳞状细胞癌患者进行前瞻性研究,按照随机数字表法分为对照组和观察组各52例。对照组予以腹腔镜宫颈癌根治术治疗,观察组在对照组基础上联合新辅助化疗。比较两组治疗前和治疗6个月后肿瘤病人生存质量(QOL)评分、血清糖类抗原125(CA125)水平、鳞状细胞癌抗原(SCC-Ag)水平和癌胚抗原(CEA)水平,淋巴结清扫数量和2年生存率,以及并发症/不良反应发生率。结果:治疗后,两组QOL评分均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组血清CA125、SCC-Ag、CEA水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组淋巴结清扫数量多于对照组,2年生存率高于对照组,差异均有统计学意义(P<0.05);两组并发症/不良反应发生率比较,差异无统计学意义(P>0.05)。结论:新辅助化疗联合腹腔镜宫颈癌根治术治疗子宫颈鳞状细胞癌患者,可提高QOL评分、2年生存率和淋巴结清扫数量,降低血清CA125、SCC-Ag、CEA水平,效果优于单纯腹腔镜宫颈癌根治术治疗。
Objective: To observe effects of neoadjuvant chemotherapy combined with laparoscopic radical resection of cervical cancer in patients with cervical squamous cell carcinoma. Methods: 104 patients with cervical squamous cell carcinoma admitted to this hospital from March 2018 to March 2019 were selected for the prospective study, and were divided into control group and observation group according to random number table method, 52 cases in each group. The control group was treated with laparoscopic radical resection of cervical cancer, while the observation group was treated with neoadjuvant chemotherapy on the basis of that of the control group. The quality of life(QOL) score, the serum carbohydrate antigen 125(CA125) level, the squamous cell carcinoma antigen(SCC-Ag) level, the carcinoembryonic antigen(CEA) level, the number of lymph node dissected, the 2-year survival rate, and incidence of complications/adverse reactions were compared between the two groups before and 6 months after the treatment. Results: After the treatment, the QOL scores of the two groups were higher than those before the treatment, that of the observation group was higher than that of the control group, and the differences were statistically significant(P<0.05). The levels of serum CA125, SCC-Ag and CEA in the two groups were lower than those before the treatment, those of the observation group were lower than those of the control group,and the differences were statistically significant(P<0.05). The number of lymph nodes dissected in the observation group was more than that in the control group, the 2-year survival rate was higher than that in the control group, and the differences were statistically significant(P<0.05). However,there was no significant difference in the incidence of complications/adverse reactions between the two groups(P>0.05). Conclusions: Neoadjuvant chemotherapy combined with laparoscopic radical resection of cervical cancer in the treatment of cervical squamous cell carcinoma can improve the QOL score, the 2-year survival rate and the number of lymph node dissected, and reduce the serum CA125, SCC-Ag and CEA levels. Moreover, it is superior to single laparoscopic radical resection of cervical cancer.
作者
刘艳
邹科
杨小卓
李中钦
LIU Yan;ZOU Ke;YANG Xiaozhuo;LI Zhongqin(nd Special Ward of Department of Gynecology of Nanyang Central Hospital,Nanyang 473000 Henan,China)
出处
《中国民康医学》
2022年第19期41-44,共4页
Medical Journal of Chinese People’s Health
关键词
新辅助化疗
腹腔镜宫颈癌根治术
子宫颈鳞状细胞癌
淋巴结
QOL评分
生存率
Neoadjuvant chemotherapy
Laparoscopic radical resection of cervical cancer
Cervical squamous cell carcinoma
Lymph node
QOL score
Survival rate
